JP Morgan has upgraded Edwards Lifesciences Corp (EW) to Overweight from Neutral, signaling a more optimistic outlook for the company. This change, effective December 17, 2025, comes as Edwards Lifesciences continues to innovate in the health care sector, particularly in patient-focused medical innovations for heart disease and critical care monitoring.
As of the last market close, Edwards Lifesciences shares traded at $85.75. The upgrade reflects a shift in analyst sentiment, potentially indicating improved fundamentals or enhanced confidence in the company's strategic direction. The firm's market capitalization stands at $49.3 billion, with a price-to-earnings ratio of 36.03 and earnings per share of $2.33.
Looking ahead, Edwards Lifesciences is scheduled to report its upcoming earnings on July 22, 2026, with earnings per share expected to be $0.75 and revenue estimated at $1.7 billion. Recent earnings performance has shown positive surprises, with Q3 2025 reporting an EPS of $0.67, exceeding estimates by 9.6%.
Analyst consensus remains favorable, with 11 Strong Buy, 18 Buy, and 13 Hold ratings among 42 total ratings. The announcement highlights the growing confidence among analysts regarding the company's future prospects in a competitive industry.